{
    "nctId": "NCT03451162",
    "briefTitle": "Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer",
    "officialTitle": "A Phase I, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of DHES0815A in Patients With HER2-Positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) With Severity Determined as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0",
    "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Measurable disease by RECIST v1.1 with at least one measurable target lesion\n* Locally advanced or metastatic HER2-positive breast cancer that has relapsed or is refractory to established therapies\n* Adequate hematologic and end-organ function\n* For dose-expansion cohort only: no more than two prior systemic chemotherapy-containing regimens in the advanced/metastatic setting (excluding trastuzumab emtansine, which is considered a targeted cytotoxic agent)\n\nKey Exclusion Criteria:\n\n* Treatment with chemotherapy, hormonal therapy (except hormone replacement therapy, oral contraceptives), immunotherapy, biologic therapy, radiation therapy (except palliative radiation to bony metastases), or herbal therapy as cancer therapy within 4 weeks prior to initiation of DHES0815A\n* History of exposure to the protocol specified doses of anthracyclines\n* Pregnancy, lactation, or breastfeeding\n* Major surgical procedure within 4 weeks prior to Day 1\n* Evidence of a significant uncontrolled concomitant disease of the nervous system, pulmonary, autoimmune, renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture\n* Known active bacterial, viral, fungal, mycobacterial, or other infection\n* Clinically significant history of liver disease, including active viral or other hepatitis, current alcohol abuse, or cirrhosis\n* Untreated or active central nervous system (CNS) metastases\n* Cardiopulmonary dysfunction, including inadequate left ventricular ejection function at baseline, less than 50% by either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)\n* QT interval corrected through use of Fridericia's formula (QTcF) \\> 470 milliseconds (ms)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}